Il trattamento multimodale del carcinoma esofageo localmente avanzato. Trial multicentrico di fase II con oxaliplatino, 5-fuoroziacile, folati ridotti e radioterapia neoadiuvanti: risultati prelirninari.

Translated title of the contribution: Multimodal treatment in locally advanced esophageal cancer: a multicenter phase II study with neoadjuvant oxaliplatin, 5-fluorouracil, leucovorin and neoadjuvant radiotherapy: preliminary results

Matteo Cagol, Alberto Ruol, Vanna Chiarion Sileni, Gian Luca De Salvo, Luigi Corti, Rita Alfieri, Roberto Innocente, Umberto Fumagalli, Riccardo Rosati, Ermanno Ancona

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aim of the study was to evaluate the feasibility and efficacy of treatment with oxaliplatin, 5-fluorouracil and leucovorin concomitant with radiation therapy in locally advanced oesophageal cancer. Fifty-eight patients with previously untreated, histologically proven oesophageal cancer were enrolled. Downstaged patients underwent either surgery or received brachytherapy. We report the results obtained in the first 54 patients. The median age was 58 years. The diagnosis was squamous cell carcinoma/adenocarcinoma/poorly differentiated: 45/8/1; clinical stage: T3N1M0 38 (70%), T4 10 (19%), M1a 6 (11%). Thirty-nine patients (72%) received the planned 8 weeks of chemotherapy and 45 completed the entire course of scheduled radiotherapy. Four (7%) toxic deaths were recorded, 2 more patients died prematurely from massive oesophageal bleeding and 1 from progression of disease. We recorded 8 (15%) complete responses and 24 (44%) partial responses. Resection was complete (R0) in 24 (80% of resected patients, 44% of treated patients). A complete pathological response was documented in 6 patients (11% of those treated). Postoperative complications were recorded in 8 (25%) patients, with 2 (6.2%) deaths. RO resection was accomplished in 44% of patients. Toxicity was moderate, but postoperative mortality was not negligible. Survival data are awaited before a phase III comparison with cisplatin-containing chemo-radiotherapy may be considered.

Original languageItalian
Pages (from-to)433-439
Number of pages7
JournalChirurgia Italiana
Volume58
Issue number4
Publication statusPublished - Jul 2006

Fingerprint

oxaliplatin
Combined Modality Therapy
Leucovorin
Esophageal Neoplasms
Fluorouracil
Radiotherapy

ASJC Scopus subject areas

  • Surgery

Cite this

@article{2996f690fa0842b0acd0e8b1f47fe9a3,
title = "Il trattamento multimodale del carcinoma esofageo localmente avanzato. Trial multicentrico di fase II con oxaliplatino, 5-fuoroziacile, folati ridotti e radioterapia neoadiuvanti: risultati prelirninari.",
abstract = "The aim of the study was to evaluate the feasibility and efficacy of treatment with oxaliplatin, 5-fluorouracil and leucovorin concomitant with radiation therapy in locally advanced oesophageal cancer. Fifty-eight patients with previously untreated, histologically proven oesophageal cancer were enrolled. Downstaged patients underwent either surgery or received brachytherapy. We report the results obtained in the first 54 patients. The median age was 58 years. The diagnosis was squamous cell carcinoma/adenocarcinoma/poorly differentiated: 45/8/1; clinical stage: T3N1M0 38 (70{\%}), T4 10 (19{\%}), M1a 6 (11{\%}). Thirty-nine patients (72{\%}) received the planned 8 weeks of chemotherapy and 45 completed the entire course of scheduled radiotherapy. Four (7{\%}) toxic deaths were recorded, 2 more patients died prematurely from massive oesophageal bleeding and 1 from progression of disease. We recorded 8 (15{\%}) complete responses and 24 (44{\%}) partial responses. Resection was complete (R0) in 24 (80{\%} of resected patients, 44{\%} of treated patients). A complete pathological response was documented in 6 patients (11{\%} of those treated). Postoperative complications were recorded in 8 (25{\%}) patients, with 2 (6.2{\%}) deaths. RO resection was accomplished in 44{\%} of patients. Toxicity was moderate, but postoperative mortality was not negligible. Survival data are awaited before a phase III comparison with cisplatin-containing chemo-radiotherapy may be considered.",
author = "Matteo Cagol and Alberto Ruol and Sileni, {Vanna Chiarion} and {De Salvo}, {Gian Luca} and Luigi Corti and Rita Alfieri and Roberto Innocente and Umberto Fumagalli and Riccardo Rosati and Ermanno Ancona",
year = "2006",
month = "7",
language = "Italian",
volume = "58",
pages = "433--439",
journal = "Chirurgia Italiana",
issn = "0009-4773",
publisher = "Bi & Gi Editori",
number = "4",

}

TY - JOUR

T1 - Il trattamento multimodale del carcinoma esofageo localmente avanzato. Trial multicentrico di fase II con oxaliplatino, 5-fuoroziacile, folati ridotti e radioterapia neoadiuvanti

T2 - risultati prelirninari.

AU - Cagol, Matteo

AU - Ruol, Alberto

AU - Sileni, Vanna Chiarion

AU - De Salvo, Gian Luca

AU - Corti, Luigi

AU - Alfieri, Rita

AU - Innocente, Roberto

AU - Fumagalli, Umberto

AU - Rosati, Riccardo

AU - Ancona, Ermanno

PY - 2006/7

Y1 - 2006/7

N2 - The aim of the study was to evaluate the feasibility and efficacy of treatment with oxaliplatin, 5-fluorouracil and leucovorin concomitant with radiation therapy in locally advanced oesophageal cancer. Fifty-eight patients with previously untreated, histologically proven oesophageal cancer were enrolled. Downstaged patients underwent either surgery or received brachytherapy. We report the results obtained in the first 54 patients. The median age was 58 years. The diagnosis was squamous cell carcinoma/adenocarcinoma/poorly differentiated: 45/8/1; clinical stage: T3N1M0 38 (70%), T4 10 (19%), M1a 6 (11%). Thirty-nine patients (72%) received the planned 8 weeks of chemotherapy and 45 completed the entire course of scheduled radiotherapy. Four (7%) toxic deaths were recorded, 2 more patients died prematurely from massive oesophageal bleeding and 1 from progression of disease. We recorded 8 (15%) complete responses and 24 (44%) partial responses. Resection was complete (R0) in 24 (80% of resected patients, 44% of treated patients). A complete pathological response was documented in 6 patients (11% of those treated). Postoperative complications were recorded in 8 (25%) patients, with 2 (6.2%) deaths. RO resection was accomplished in 44% of patients. Toxicity was moderate, but postoperative mortality was not negligible. Survival data are awaited before a phase III comparison with cisplatin-containing chemo-radiotherapy may be considered.

AB - The aim of the study was to evaluate the feasibility and efficacy of treatment with oxaliplatin, 5-fluorouracil and leucovorin concomitant with radiation therapy in locally advanced oesophageal cancer. Fifty-eight patients with previously untreated, histologically proven oesophageal cancer were enrolled. Downstaged patients underwent either surgery or received brachytherapy. We report the results obtained in the first 54 patients. The median age was 58 years. The diagnosis was squamous cell carcinoma/adenocarcinoma/poorly differentiated: 45/8/1; clinical stage: T3N1M0 38 (70%), T4 10 (19%), M1a 6 (11%). Thirty-nine patients (72%) received the planned 8 weeks of chemotherapy and 45 completed the entire course of scheduled radiotherapy. Four (7%) toxic deaths were recorded, 2 more patients died prematurely from massive oesophageal bleeding and 1 from progression of disease. We recorded 8 (15%) complete responses and 24 (44%) partial responses. Resection was complete (R0) in 24 (80% of resected patients, 44% of treated patients). A complete pathological response was documented in 6 patients (11% of those treated). Postoperative complications were recorded in 8 (25%) patients, with 2 (6.2%) deaths. RO resection was accomplished in 44% of patients. Toxicity was moderate, but postoperative mortality was not negligible. Survival data are awaited before a phase III comparison with cisplatin-containing chemo-radiotherapy may be considered.

UR - http://www.scopus.com/inward/record.url?scp=33750617023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750617023&partnerID=8YFLogxK

M3 - Articolo

C2 - 16999147

AN - SCOPUS:33750617023

VL - 58

SP - 433

EP - 439

JO - Chirurgia Italiana

JF - Chirurgia Italiana

SN - 0009-4773

IS - 4

ER -